Atul Deodhara (Oregon Health & Science University, Portland, OR, USA) kindly discusses the phase III results of the oral JAK inhibitor, tofacitinib, in the treatment of adult patients with Ankylosing Spondylitis. His abstract entitled: ‘Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study’ (NCT03502616) was presented at the ACR Convergence 2020, 5-9 November 2020.
Questions
- What is the rationale for the use of JAK inhibitors in the treatment of ankylosing spondylitis (AS)? (0:16)
- Could you tell me a little about the aims, design and eligibility criteria for the Phase III clinical study you presented investigating tofacitinib in the treatment of AS? (1:40)
- What were the major efficacy findings from the primary analysis of this study? (2:56)
- What were the major safety findings? (3:58)
- What do you think will be the next steps in the clinical development of tofacitinib, and other JAK inhibitors, in the treatment of ankylosing spondylitis? (4:57)
Disclosures: Atul Deodhar has acted as a consultant/participated in advisory boards for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Glaxo Smith & Kline, Janssen, Novartis, Pfizer and UCB. He has also received research grants from AbbVie, Eli Lilly, Glaxo Smith & Kline, Novartis, Pfizer and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of virtual ACR Convergence 2020.
